Sponsor or institution
Clinical trials and research at MediLink Therapeutics (Suzhou) Co., Ltd.
As of November 12, 2026, Find a Trial lists 17 clinical trials run by MediLink Therapeutics (Suzhou) Co., Ltd. that are recruiting, at sites in 12 countries (most in China (16), United States (6), Australia (2)). By phase: Phase 1/2 (7), Phase 2 (4), Phase 3 (4), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 17Clinical trials
- 12Countries
Newest trials
All recruiting trials (17)
-
YL201 plus serplulimab vs the usual chemo combo as first treatment for extensive-stage small cell lung cancer
This trial tests whether adding YL201 to serplulimab can improve outcomes compared with standard carboplatin and etoposide plus serplulimab in adults with treatment-naïve extensive-stage SCLC.
-
YL201 vs physician's choice chemotherapy in advanced esophageal squamous cell carcinoma
This study tests whether a new drug called YL201 works better or is safer than standard chemotherapy in adults with advanced or metastatic esophageal squamous cell cancer whose first treatment stopped helping.
-
YL202 vs physician's choice in HR+/HER2- breast cancer
This trial tests YL202 against a physician's choice of approved drugs in people with HR+/HER2- breast cancer that has spread or cannot be surgically removed and who have had at least one prior chemotherapy.
-
YL202 vs Docetaxel in EGFR-mutated NSCLC after prior therapy
This trial tests whether YL202 works better than Docetaxel for adults with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have already had EGFR TKI and platinum chemotherapy.
-
YL201 plus atezolizumab for newly diagnosed extensive-stage small cell lung cancer
This trial will try YL201 together with atezolizumab to see if the combo is safe and helpful for people with newly diagnosed extensive-stage small cell lung cancer.
-
YL201 with toripalimab, with or without cisplatin, for recurrent or metastatic nasopharyngeal carcinoma
This trial tests whether adding the experimental drug YL201 to toripalimab, with or without cisplatin, can help people with recurrent or metastatic nasopharyngeal carcinoma.
-
Combination of YL201 and ivonescimab (AK112) for advanced solid tumors
This trial will test whether combining YL201 and ivonescimab (AK112) helps people with advanced solid tumors, including non‑small cell and small cell lung cancer.
-
YL202 for advanced non‑small cell lung, colorectal, cervical, and other solid tumors
This trial will try YL202, an antibody‑drug conjugate that targets HER3, in adults with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors who have received one or two prior systemic treatments.
-
YL242 treatment for people with advanced solid tumors
This trial will test YL242 alone and with pembrolizumab or chemotherapy in adults with advanced or metastatic solid tumors to check safety and early activity.
-
YL202 combined with immunotherapy or targeted therapy for advanced solid tumors
This trial tests whether adding YL202 to other anti-tumor treatments helps adults with advanced solid tumors (including breast cancer and non‑small cell lung cancer) tolerate therapy and control tumor growth.
-
First-in-human use of YL217 for adults with advanced solid tumors
This Phase 1 test gives a new antibody-drug conjugate called YL217 to see if it is safe and helps adults with advanced solid tumors.
-
Evaluating YL205 for patients with advanced solid tumors
This study is testing a new treatment called YL205 to see if it helps people with advanced solid tumors, like certain types of ovarian and lung cancer, feel better and manage their disease.
-
Evaluating YL202 for advanced breast cancer treatment
This study is testing a new treatment called YL202 for people with advanced breast cancer who haven't had success with other therapies and can't have surgery or radiation.
-
Evaluating YL211 for patients with advanced solid tumors
This study is testing a new treatment called YL211 to see if it is safe and effective for people with advanced solid tumors.
-
Evaluating YL201 for treating advanced prostate cancer
This study is testing a new injection treatment called YL201 to see if it can help people in China with advanced prostate cancer feel better and improve their condition.
-
Evaluating YL202 for Patients with Advanced Solid Tumors
This study is testing a new treatment called YL202 to see if it can help people with advanced solid tumors like lung, breast, and head and neck cancers feel better.
-
Testing YL201 in patients with advanced solid tumors
This study is testing a new treatment called YL201 in people with advanced solid tumors that haven't responded to other treatments to see how well it works and what dose is safe.
Quick answers
How many clinical trials run by MediLink Therapeutics (Suzhou) Co., Ltd. are recruiting right now?
17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 12 countries. The most sites are in China (16 trials), United States (6 trials), Australia (2 trials), Canada (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 7, Phase 2: 4, Phase 3: 4, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.